HRP20040370B1 - Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder - Google Patents

Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder

Info

Publication number
HRP20040370B1
HRP20040370B1 HRP20040370AA HRP20040370A HRP20040370B1 HR P20040370 B1 HRP20040370 B1 HR P20040370B1 HR P20040370A A HRP20040370A A HR P20040370AA HR P20040370 A HRP20040370 A HR P20040370A HR P20040370 B1 HRP20040370 B1 HR P20040370B1
Authority
HR
Croatia
Prior art keywords
estra
benzodioxol
dien
propynyl
hydroxy
Prior art date
Application number
HRP20040370AA
Other languages
English (en)
Croatian (hr)
Inventor
Sennef Cornelis
Wijnand Mathys Marie Peeters Bernardus
Original Assignee
Pop Test Cortisol Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pop Test Cortisol Llc filed Critical Pop Test Cortisol Llc
Publication of HRP20040370A2 publication Critical patent/HRP20040370A2/hr
Publication of HRP20040370B1 publication Critical patent/HRP20040370B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20040370AA 2001-10-26 2004-04-26 Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder HRP20040370B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
PCT/EP2002/011732 WO2003037354A1 (en) 2001-10-26 2002-10-21 USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Publications (2)

Publication Number Publication Date
HRP20040370A2 HRP20040370A2 (en) 2004-08-31
HRP20040370B1 true HRP20040370B1 (en) 2012-09-30

Family

ID=8181136

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20040370AA HRP20040370B1 (en) 2001-10-26 2004-04-26 Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder

Country Status (27)

Country Link
US (1) US20040266863A1 (ko)
EP (2) EP1441739B1 (ko)
JP (1) JP4647909B2 (ko)
KR (1) KR20050038580A (ko)
CN (1) CN100531738C (ko)
AT (2) ATE420649T1 (ko)
AU (1) AU2002348996B2 (ko)
BR (1) BR0213466A (ko)
CA (1) CA2463446C (ko)
CY (1) CY1110173T1 (ko)
DE (2) DE60209248D1 (ko)
DK (1) DK1652526T3 (ko)
EC (1) ECSP045080A (ko)
ES (1) ES2319563T3 (ko)
HK (1) HK1087357A1 (ko)
HR (1) HRP20040370B1 (ko)
HU (1) HUP0500070A3 (ko)
IL (2) IL161248A0 (ko)
IS (1) IS2702B (ko)
MX (1) MXPA04003781A (ko)
NO (1) NO332978B1 (ko)
NZ (1) NZ532429A (ko)
PL (1) PL206687B1 (ko)
PT (1) PT1652526E (ko)
RU (1) RU2302245C2 (ko)
WO (1) WO2003037354A1 (ko)
ZA (1) ZA200403088B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
US20080255074A1 (en) * 2004-11-19 2008-10-16 N.V. Organon Drug Combination Comprising A Selective Serotonin Reuptake Inhibitor And A Glucocorticoid Receptor Antagonist For The Treatment Of Depression
CA2649894A1 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
JP5804395B2 (ja) * 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
WO2012145258A1 (en) * 2011-04-18 2012-10-26 Pop Test Cortisol Llc Hair loss treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
EP0763541A1 (en) * 1995-08-17 1997-03-19 Akzo Nobel N.V. 11-(Substituted phenyl)-estra-4,9-diene derivatives
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2002076390A2 (en) * 2001-03-23 2002-10-03 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
ES2314103T3 (es) * 2001-08-31 2009-03-16 Corcept Therapeutics, Inc. Metodo para inhibir deterioro cognitivo en adultos con sindrome de down.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
EP0763541A1 (en) * 1995-08-17 1997-03-19 Akzo Nobel N.V. 11-(Substituted phenyl)-estra-4,9-diene derivatives
WO1999017779A1 (en) * 1997-10-06 1999-04-15 The Board Of Trustees Of Leland Stanford Jr. University Methods for treating psychosis associated with glucocorticoid related dysfunction
WO2002076390A2 (en) * 2001-03-23 2002-10-03 Corcept Therapeutics, Inc. Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
WO2002096433A1 (en) * 2001-05-04 2002-12-05 Corcept Therapeutics, Inc. Methods for treating delirium using glucocorticoid receptor-specific antagonists

Also Published As

Publication number Publication date
ATE420649T1 (de) 2009-01-15
EP1652526B1 (en) 2009-01-14
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
EP1652526A2 (en) 2006-05-03
JP2005521637A (ja) 2005-07-21
IL161248A0 (en) 2004-09-27
US20040266863A1 (en) 2004-12-30
MXPA04003781A (es) 2004-07-30
KR20050038580A (ko) 2005-04-27
BR0213466A (pt) 2004-11-09
HK1087357A1 (en) 2006-10-13
IS7204A (is) 2004-03-31
CA2463446A1 (en) 2003-05-08
HUP0500070A3 (en) 2012-09-28
ECSP045080A (es) 2004-06-28
CA2463446C (en) 2010-02-23
IL161248A (en) 2010-12-30
DE60230936D1 (de) 2009-03-05
HRP20040370A2 (en) 2004-08-31
NZ532429A (en) 2004-10-29
PL206687B1 (pl) 2010-09-30
ES2319563T3 (es) 2009-05-08
JP4647909B2 (ja) 2011-03-09
DE60209248D1 (de) 2006-04-20
PL369261A1 (en) 2005-04-18
EP1441739A1 (en) 2004-08-04
ATE317700T1 (de) 2006-03-15
ZA200403088B (en) 2005-01-24
EP1441739B1 (en) 2006-02-15
WO2003037354A1 (en) 2003-05-08
IS2702B (is) 2010-11-15
PT1652526E (pt) 2009-02-06
NO332978B1 (no) 2013-02-11
HUP0500070A2 (hu) 2005-04-28
CN1582153A (zh) 2005-02-16
AU2002348996B2 (en) 2008-06-05
CN100531738C (zh) 2009-08-26
CY1110173T1 (el) 2015-01-14
DK1652526T3 (da) 2009-05-18
EP1652526A3 (en) 2006-08-02
RU2004116082A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MY127290A (en) New use of flibanserin
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
AR049112A1 (es) Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual
HK1068606A1 (en) Novel aminobenzoephenones
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
HRP20040370B1 (en) Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
GB0010683D0 (en) Cancer therapy
AU3885799A (en) Antidepressant therapy
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
JP2005521637A5 (ko)
NO20072687L (no) Farmasoytisk prevensjonspreparat
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
RS50350B (sr) Upotreba 11beta-(4-acetilfenil)-17beta-hidroksi-17alfa-(1,1,2,2,2-pentafluoretil)estra-4,9-dien-3-ona za pripremanje medikamenta za lečenje kancera dojke, jajnika, endometrijuma, mijeloma i meningioma
IL162391A (en) Use of darifenacin in the manufacture of medicaments for reducing urgency in dry overactive bladder patients
CA2403674A1 (en) The use of t3 for treating congestive heart failure
HRP20020666B1 (en) Drospirenone for hormone replacement therapy
DK1937274T3 (da) Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception
EP1759734A3 (en) Aromatase inhibition to enhance assisted reproduction

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: N.V. ORGANON, NL

PPPP Transfer of rights

Owner name: POP TEST CORTISOL LLC, US

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20121011

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20131021